OrganiGram Holdings (TSE:OGI) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Organigram Holdings Inc. has announced promising preliminary results from a clinical study on its new FAST™ nanoemulsion technology, which offers a faster onset and improved bioavailability of cannabinoids for ingestible products. The technology is set to enhance Organigram’s product line, providing consumers with more control over their dosage experience. Final results of the study, which could significantly impact the adult-use cannabis market, are expected to be published later this year.
For further insights into TSE:OGI stock, check out TipRanks’ Stock Analysis page.